The Translational Pathology Core provides normal and tumor tissue specimens necessary for the laboratory-based, epidemiologic and clinical studies being conducted by USC Norris Comprehensive Cancer Center (KiCCC) investigators. As cancer research increasingly utilizes human tumor specimens, the need for this service has escalated accordingly. It is now indispensable for many NCCC investigators. Tissue specimens have been provided to 24 NCCC members with active peer-reviewed research funding. The Core is organized into three arms, each with distinct but related functions;the Adult Tissue Arm (ATA) supervised by Dr. Andrew Sherrod, supplies fresh/frozen adult normal and tumor tissue and fluid specimens, the Pediatric Tissue Arm (PTA) supervised by Dr. Hiroyuki Shimada, provides pediatric tumor tissue specimens, and the Population Based Tissue Arm (PBTA) supervised by Dr. Wendy Cozen, provides population-based, fixed tissue specimens primarily for epidemiologic studies. Overall, coordination of these services is under the direction of Dr. Sue Ellen Martin. By using this Core, NCCC investigators were able to identify molecular markers associated with tumor recurrence in 250 patients with stage 2 and 3 colon cancer and 103 stage 1-3 gastric cancer, collaborated with the Broad Institute on the 8q24 pathway getting 100 fresh tissues leading to a Nature Genetics publication, publish a molecular classification of childhood rhabdomyosarcoma based on genotypic and phenotypic determinants that distinguish two major prognostic groups, and identified an ethnic-specific tumor marker for prostate cancer.

Public Health Relevance

Normal and diseased tissues which are fresh/frozen or obtained from paraffin blocks are indispensible for translational cancer research. This Core with these arms provides fresh/frozen tissue from pediatric and adult subjects. It also has a unique ability to provide population-based fixed specimens for epidemiological studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-39
Application #
8589354
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$631,729
Indirect Cost
$229,876
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications